The present invention pertains to a medical device for providing a leak-resistant seal for use in a vascular access device.
When interventional catheter devices are inserted into the vascular system, the physician usually starts with a needle stick, followed by dilating the artery in order to insert an introducer sheath device that is left in place for the duration of the procedure. This introducer sheath acts as the main conduit for entry of subsequent therapeutic or diagnostic devices. In most instances, these introducer sheaths contain a hemostatic component that restricts back-flow of blood from the artery. These hemostasis seals are generally passive and provide sealing around the catheter devices and guide wires that are used during the procedure.
Current devices and prior art for hemostasis seals have limited performance when they are made for large size devices. This is due to the extreme size difference between the large catheter device and the much smaller guide wire used in these procedures. When larger catheter devices are used (such as 14-20 Fr), it can be difficult to seal on both this large diameter and on the guide wires used in these types of procedures, which are generally 0.035″ in diameter. Current seals tend to leak when only the guide wire is in place or when nothing is in place, especially after large diameter devices have passage through the sealing device and have stretched or damaged the seal in the process.
It is the objective of this invention to provide a hemostasis sealing device for large bore interventional devices that provides a leak-proof or leak resistant blood seal on both guide wire passage as well as device passage through the seal.
The present invention is directed to a device for vascular access, in particular a hemostasis sealing device that has a first seal for large device sealing and a second seal for guide wire sealing. The first seal is often formed using a hole seal or a wring seal, while the second seal is often formed using a split, septum seal. The split, septum seal can optionally be held by compression with a mating housing. In some implementations the second, guide wire seal comprises an extended barrel portion to inhibit seal inversion or misalignment. The hemostasis sealing device can include support ring configured for compressive interface with a housing. The second seal may comprise a single axial split approximately forty five degrees offset from the support ribs.
The above summary of the present invention is not intended to describe each disclosed embodiment of the present invention. This is the purpose of the detailed description and claims that follows.
The invention may be more completely understood in consideration of the following detailed description of various embodiments of the invention in connection with the accompanying drawings, in which:
These drawings are to be considered general representations of the invention, and it will be appreciated that they are not drawn to encompass all embodiments of the invention, nor are they always drawn to scale. While the invention is susceptible to various modifications and alternative forms, specifics thereof have been shown by way of example and drawings, and will be described in detail. It should be understood, however, that the invention is not limited to the particular embodiments described. On the contrary, the intention is to cover modifications, equivalents, and alternatives falling within the spirit and scope of the invention.
The present invention is directed to a device for vascular access, in particular a hemostasis sealing device that has a first seal portion for device sealing and a second seal portion for guide wire sealing. As a vascular access device is passed over a guide wire during a procedure, the device passes through a first seal portion which stretches and seals around the medical device. While the second seal portion is generally configured for guide wire sealing, a split defined by the second seal portion allows passage of relatively large bore devices.
The first seal portion can be a hole seal or a wring seal, while the second seal portion can be a split, septum seal. The hemostasis sealing device generally has structural elements that are configured to structurally support the second seal portion for sealing. In a variety of embodiments, the second seal portion is held in compression by a housing that compressively interfaces with the hemostasis sealing device. In such an embodiment, support ribs can be in compressive communication with the second seal portion. The split of the second seal portion can be an axial split offset from the support ribs. In some implementations a barrel extends from the second seal portion to inhibit seal inversion or misalignment.
An example embodiment of such a hemostasis sealing device is shown in
The hemostasis sealing device 100 is generally configured to provide a fluid seal for vascular access devices and simultaneously allowing translation or movement of a guide wire while providing a fluid seal there-around. The hemostasis sealing device 100 can be constructed of a variety of materials such as, for example, silicone rubber in the range of 10-60 Shore A durometer. In another example, the hemostasis sealing device 100 can be constructed so as to contain nitinol elements. Those having skill in the art will recognize that the hemostasis sealing device 100 can be constructed of various thermoplastic elastomers, and combinations thereof, available and known.
The hemostasis sealing device 100 is configured to be received by the distal end 214 of the housing 200. In at least one embodiment the hemostasis sealing device 100 is in compression upon being received by the housing 200. In one embodiment the compression of the hemostasis sealing device 100 is in the range of 0-5% of the diameter of the seal body. This compression allows the sealing device 100 to be firmly held within the housing 200.
The hemostasis sealing device 100 has a device enclosure 120 defining a device cavity 122 and, as mentioned above, has the first seal portion 110 and the second seal portion 130. The first seal portion 110 is generally configured to provide a seal for a medical device passing into the device cavity 122, such as a vascular access device, and the second seal portion 130 is generally configured to provide a seal for a guide wire. The device cavity 122 is generally sized to receive at least a portion of the medical device.
In this particular embodiment, the support ring 150 has a radial flange 152 and is received by a ring receptacle 220 defined by the housing 200. In some embodiments, the support ring 150 will be relatively rigid compared to some portions of the hemostasis sealing device 100. An outer annular surface 124 of the hemostasis sealing device 100 is received by the distal end 214 of the passageway 210 of the housing 200. In at least one embodiment, the housing 200 exerts compressive force on the outer annular surface 124 of the hemostasis sealing device 100.
The first seal portion 110 is generally elastomeric and defines a first seal opening 112 that is sized to seal around the medical device passing there-through. In one embodiment, the first seal portion 110 is a sealing hole. In another embodiment, the first seal portion 110 is a sealing ring. Typically the first seal opening 112 defined by the first seal portion 110 is sized in the range of 0.2-0.4 times the diameter of the largest device size that is to be inserted through a given seal. For instance, for a 20 Fr device (0.260 in. diameter), the first seal opening 112 size would be in the range of 0.052-0.104 in. in diameter.
The second seal portion 130 is similarly elastomeric to the first seal portion 110 and defines a split 102 there-through. The split 102 will generally be axial relative to the second seal portion 130, and can also be axial relative to the hemostasis sealing device 100 itself. In a variety of embodiments, the second seal portion 130 has a thickness in the range of 0.005-0.020 inches and a diameter in the range of 0.9-1.3 times the diameter of the guide wire to be used. Given the size differential between the first seal portion 110 and the second seal portion 130, in the current embodiment, the cross section of the device cavity 122 generally tapers towards the second seal portion 130. Those having skill in the art will recognize that the second seal portion 130 can be consistent with a split septum seal. In a variety of embodiments, structural elements of the hemostasis sealing device 100 are configured to provide structural support to the second seal portion 130. As one example, the compression fit between the hemostasis sealing device 100 and the housing 200 compresses the second seal portion 130 at the split 102 to be in sealing engagement with a guide wire.
A barrel 140 of the hemostasis sealing device 100 generally extends from the second seal portion 130. The barrel 140 is generally annular and coaxial with the second seal portion 130. The barrel 140 defines a barrel opening 142, a substantial portion of which is cylindrical in shape. The barrel 140 is generally configured to provide structural support to the second seal portion 130. In at least one embodiment, the barrel 140 prevents the split 102 of the second seal portion 130 from becoming misaligned and/or inverted on itself, wherein misalignment and inversion can inhibit complete sealing.
The split 102 is generally defined from the proximal end 104 of the hemostasis sealing device 100, through the barrel 140 and the device enclosure 120, and extending towards the support ring 150. In a variety of embodiments the split 102 does not extend through the support ring 150 or the first seal portion 110. In a variety of implementations, it can be desirable for the hemostasis sealing device 100 to allow passage of large-bore devices, and the split 102 defined by the hemostasis sealing device 100 can accommodate such a use.
A tapered portion 126 of the device enclosure 120 extends between the outer annular portion 124 of the device enclosure 120 and the barrel 140. The tapered portion 126 can generally correspond with the tapered shape of the device cavity 122 and can extend adjacent to the second seal portion 130 (See
In a variety of implementations the hemostasis sealing device 100 includes two or more support ribs 170 along the tapered portion 124 of the device enclosure 120 in compressive communication with at least a portion of the split 102. As depicted in
In the current embodiment, an outer end surface 172 of each support rib 170 is coplanar with the outer annular surface 124 of the device enclosure 120. As such, the outer annular surface 124 of the device enclosure 120, the outer end surface 172 of each support rib 170 is configured for compressive interfacing with the inner annular surface 240 of the housing 200 (See
It can be desirable to stagger the split 102 defined by the hemostasis sealing device 100 relative to the support ribs 170 such that relatively symmetrical compressive forces are applied about the second seal portion 130. In the current embodiment, the support ribs 170 are symmetrical relative to the split 102. The split 102 is offset from the support ribs 170 by about 45 degrees. Other configurations of support ribs relative to a split defined by a hemostasis sealing device are also possible.
Visible in
In the embodiment depicted in
In the current embodiment the first seal portion 410 has a radial lip 414 extending into the device cavity 422 that at least partially defines a first seal opening 412. The radial lip 414 is generally configured to contribute to device sealing around a medical device.
The support ring 450 can be coupled to the device enclosure 420 through a variety of ways that will be known in the art. In one embodiment an adhesive is disposed between the support ring 450 and the device enclosure 420 to couple the components. In another embodiment the support ring flange 452 threadably engages a mating structure 480 defined by the device enclosure 420. The mating structure 480 can include a mating flange 482 that is configured to be concentric to the flange 452 of the support ring 450. The mating flange 482 can define a threaded surface that is configured to be received by the support ring flange 452. In some embodiments the support ring 450 is configured to be permanently fixed to the device enclosure 460. In other embodiments the support ring 450 is configured to be removably fixed to the device enclosure 460. Other configurations will be appreciated by those having skill in the art.
The above specification provides a complete description of the present invention. Since many embodiments of the invention can be made without departing from the spirit and scope of the invention, the invention resides in the claims hereinafter appended.
This application claims the benefit of U.S. Provisional Application No. 61/447,496, filed Feb. 28, 2011, the contents of which are herein incorporated by reference.
Number | Name | Date | Kind |
---|---|---|---|
4960412 | Fink | Oct 1990 | A |
5092857 | Fleischhacker | Mar 1992 | A |
5114408 | Fleischhaker et al. | May 1992 | A |
5125903 | McLaughlin et al. | Jun 1992 | A |
5195980 | Catlin | Mar 1993 | A |
5207649 | Aruny | May 1993 | A |
5269764 | Vetter et al. | Dec 1993 | A |
5300033 | Miller | Apr 1994 | A |
5304156 | Sylvanowicz et al. | Apr 1994 | A |
5312362 | Pfolsgraf et al. | May 1994 | A |
5324271 | Abiuso et al. | Jun 1994 | A |
5336192 | Palestrant | Aug 1994 | A |
5443452 | Hart et al. | Aug 1995 | A |
5453095 | Davila | Sep 1995 | A |
5456284 | Ryan et al. | Oct 1995 | A |
5507732 | Mcclure et al. | Apr 1996 | A |
5520655 | Davila et al. | May 1996 | A |
5549576 | Patterson et al. | Aug 1996 | A |
5603702 | Smith et al. | Feb 1997 | A |
5613956 | Patterson et al. | Mar 1997 | A |
5643227 | Stevens | Jul 1997 | A |
5702370 | Sylvanowicz et al. | Dec 1997 | A |
5858007 | Fagan et al. | Jan 1999 | A |
5935112 | Stevens et al. | Aug 1999 | A |
6024729 | Dehdashtian et al. | Feb 2000 | A |
6053861 | Grossi | Apr 2000 | A |
6086570 | Aboul-Hosn et al. | Jul 2000 | A |
6142981 | Heck et al. | Nov 2000 | A |
6551283 | Guo et al. | Apr 2003 | B1 |
6632200 | Guo et al. | Oct 2003 | B2 |
6702255 | Dehdashtian | Mar 2004 | B2 |
6712791 | Lui et al. | Mar 2004 | B2 |
7081106 | Guo et al. | Jul 2006 | B1 |
7101353 | Lui et al. | Sep 2006 | B2 |
7241276 | Argentine et al. | Jul 2007 | B2 |
7582070 | Goode et al. | Sep 2009 | B2 |
7628774 | Fangrow, Jr. | Dec 2009 | B2 |
7731694 | Becker | Jun 2010 | B2 |
7901379 | Argentine et al. | Mar 2011 | B2 |
7938806 | Fisher et al. | May 2011 | B2 |
7976503 | Khan | Jul 2011 | B2 |
8016791 | Sugiki et al. | Sep 2011 | B2 |
8048033 | Becker | Nov 2011 | B2 |
8096976 | Sugiki et al. | Jan 2012 | B2 |
8137321 | Argentine | Mar 2012 | B2 |
8177760 | Rome et al. | May 2012 | B2 |
8246585 | Schennib | Aug 2012 | B2 |
8273059 | Nardeo et al. | Sep 2012 | B2 |
8444628 | Fangrow, Jr. | May 2013 | B2 |
8523822 | Nardeo et al. | Sep 2013 | B2 |
8790309 | Goode et al. | Jul 2014 | B2 |
8870850 | Fangrow, Jr. | Oct 2014 | B2 |
9005172 | Chung | Apr 2015 | B2 |
9522266 | Sutton | Dec 2016 | B2 |
10835731 | Sutton | Nov 2020 | B2 |
20030050604 | Lui et al. | Mar 2003 | A1 |
20040260243 | Rickerd | Dec 2004 | A1 |
20050020981 | Kurth | Jan 2005 | A1 |
20090012476 | Catlin | Jan 2009 | A1 |
20090259175 | Nordgren | Oct 2009 | A1 |
20100241078 | Barnes | Sep 2010 | A1 |
20100292638 | Becker et al. | Nov 2010 | A1 |
20100331784 | Fisher et al. | Dec 2010 | A1 |
20120221024 | Sutton et al. | Aug 2012 | A1 |
20120245527 | Stephens et al. | Sep 2012 | A1 |
20140343512 | Fischer et al. | Nov 2014 | A1 |
20150157843 | Pepin et al. | Jun 2015 | A1 |
20170087349 | Sutton | Mar 2017 | A1 |
Number | Date | Country |
---|---|---|
WO-2012118852 | Sep 2012 | WO |
Entry |
---|
US 5,520,663 A, 05/1996, Patterson et al. (withdrawn) |
“U.S. Appl. No. 13/407,568, Response filed Jul. 1, 2016 to Non Final Office Action dated Mar. 1, 2016”, 14 pgs. |
“U.S. Appl. No. 13/407,569, Final Office Action dated May 21, 2014”, 14 pgs. |
“U.S. Appl. No. 13/407,569, Final Office Action dated Aug. 10, 2015”, 19 pgs. |
“U.S. Appl. No. 13/407,569, Non Final Office Action dated Mar. 1, 2016”, 19 pgs. |
“U.S. Appl. No. 13/407,569, Non Final Office Action dated Jul. 31, 2013”, 8 pgs. |
“U.S. Appl. No. 13/407,569, Non Final Office Action dated Nov. 13, 2014”, 15 pgs. |
“U.S. Appl. No. 13/407,569, Notice of Allowance dated Aug. 9, 2016”, Examiner Interview Summary dated Aug. 9, 2016 included, 10 pgs. |
“U.S. Appl. No. 13/407,569, PTO Response to Rule 312 Communication dated Nov. 17, 2016”, 2 pgs. |
“U.S. Appl. No. 13/407,569, Response filed Jan. 31, 2014 to Non Final Office Action dated Jul. 31, 2013”, 10 pgs. |
“U.S. Appl. No. 13/407,569, Response filed Feb. 10, 2016 to Final Office Action dated Aug. 10, 2015”, 17 pgs. |
“U.S. Appl. No. 13/407,569, Response filed May 13, 2015 to Non Final Office Action dated Nov. 13, 2014”, 10 pgs. |
“U.S. Appl. No. 13/407,569, Response filed Oct. 21, 2014 to Final Office Action dated May 21, 2014”, 17 pgs. |
“U.S. Appl. No. 15/348,772, Final Office Action dated Jul. 8, 2019”, 16 pgs. |
“U.S. Appl. No. 15/348,772, Non Final Office Action dated Jan. 23, 2019”, 18 pgs. |
“U.S. Appl. No. 15/348,772, Non Final Office Action dated Jan. 29, 2020”, 6 pgs. |
“U.S. Appl. No. 15/348,772, Notice of Allowance dated Jul. 15, 2020”, 7 pgs. |
“U.S. Appl. No. 15/348,772, Preliminary Amendment filed Dec. 15, 2016”, 7 pgs. |
“U.S. Appl. No. 15/348,772, Response filed Jan. 8, 2020 to Final Office Action dated Jul. 8, 2019”, 16 pgs. |
“U.S. Appl. No. 15/348,772, Response filed May 23, 2019 to Non Final Office Action dated Jan. 23, 2019”, 16 pgs. |
“Application Serial No. PCT/US2012/027012, International Preliminary Report on Patentability dated Sep. 12, 2013”, 6 pgs. |
“International Application Serial No. PCT/US2007/072357, International Search Report dated Aug. 12, 2008”, 2 pgs. |
“International Application Serial No. PCT/US2007/072357, Written Opinion dated Aug. 12, 2008”, 6 pgs. |
Number | Date | Country | |
---|---|---|---|
20210236791 A1 | Aug 2021 | US |
Number | Date | Country | |
---|---|---|---|
61447496 | Feb 2011 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15348772 | Nov 2016 | US |
Child | 17073884 | US | |
Parent | 13407569 | Feb 2012 | US |
Child | 15348772 | US |